Status:
UNKNOWN
Imaging of the Angiofibrotic Switch in Neovascular AMD
Lead Sponsor:
Medical University of Vienna
Conditions:
Age-related Macular Degeneration
Choroidal Neovascularization
Eligibility:
All Genders
50+ years
Brief Summary
The content of this research project is to identify the angiofibrotic switch, the transition from angiogenesis to fibrosis, in neovascular age-related macular degeneration (nAMD) longitudinally. Despi...
Detailed Description
Research questions/hypotheses: Age-related macular degeneration (AMD) is the main cause of legal blindness among elderly patients in industrialized countries. The main reason for severe and irreversib...
Eligibility Criteria
Inclusion
- Chronic neovascular AMD with anti-VEGF treatment of a minimum duration of 12 months (cohort 1)
- Treatment-naïve active neovascular AMD (cohort 2)
- 50 years of age or older
- Visual acuity 20/25-20/320
- At least one druse (\>63μm) in either eye or late AMD in the fellow eye
- Fibrosis \<50% of total lesion area at baseline (cohort 2)
Exclusion
- Previous treatment for CNV in the study eye (cohort 2)
- Presence of other progressive retinal disease likely to affect visual acuity
- Contraindications for treatment with anti-VEGF
- Pregnancy
- Dyslexia
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 28 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03838679
Start Date
May 1 2019
End Date
April 28 2022
Last Update
February 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090